On January 3, 2018 Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, reported that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 36th Annual JP Morgan Healthcare Conference on January 11 at 11:00 a.m. PST (2:00 p.m. EST), in room Elizabethan D (Press release, Constellation Pharmaceuticals, JAN 3, 2018, View Source [SID1234522848]). The conference is being held January 8-11 at the Westin St. Francis in San Francisco, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 3, 2018 GeneCentric Therapeutics, Inc. reported a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC) (Press release, GeneCentric Therapeutics, JAN 3, 2018, View Source [SID1234522885]). As part of the research collaboration, GeneCentric will apply its lung cancer subtyping profilers (LSP) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes. Financial terms were not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GeneCentric’s proprietary core technology, CSP, identifies biologic subtypes of cancer through an integrated analysis of tumor genomics. The subtypes, which combine gene expression data with disease-related molecular pathways and immune cell expression have potential to function as universal biomarkers of drug response and enable more precision drug development. GeneCentric’s Lung Cancer Profilers (LSP 210 and LSP 220) define molecular subtypes of the two most common forms of NSCLC, adenocarcinoma and squamous cell carcinoma. Published studies have demonstrated that the subtypes, while indistinguishable by standard morphology, have different genetic, molecular and clinical attributes, and immune profiles that may drive drug response.

"G1T38 is a novel and promising targeted therapeutic with potential in many cancers," said Myla Lai-Goldman, M.D., CEO of GeneCentric. "This collaboration could identify subtypes of lung cancer where the compound is most likely to be efficacious."

On January 3, 2018 Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group Ltd. entered a license and collaboration agreement to develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer. (Press release, AngioChem, JAN 3, 2018, View Source [SID1234573598]). Xinogen was granted exclusive rights to develop and commercialize ANG1005 in the Greater China region. In return, Angiochem will receive upfront and milestone payments as well as a royalty based on future product sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Angiochem is currently developing ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer. The company’s next clinical trial is due to start in 2018.

"Angiochem is looking forward to collaborating with Xinogen," said John Huss, Executive Chairman of Angiochem. Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd, also expressed his enthusiasm and confidence about collaborating with Angiochem.

On January 3, 2018 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 36th annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2018 at 3:30 p.m. Pacific Time (Press release, BioCryst Pharmaceuticalsa, JAN 3, 2018, View Source [SID1234522831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at View Source

On January 3, 2018 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 4:30 pm (PT) (Press release, Five Prime Therapeutics, JAN 3, 2018, View Source [SID1234522849]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source or directly at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.